This study looks at how well and how safely two different treatment combinations work for people with follicular lymphoma (a type of blood cancer). Mosunetuzumab and lenalidomide (M + Len) are compared to rituximab and lenalidomide (R + Len). Participants have follicular lymphoma that hasn't responded well to other treatments. To join, patients need a certain health level (ECOG score of 0, 1, or 2), must have tried at least one other treatment, and can provide a tumor sample. Importantly, both men and women must agree to use birth control to prevent pregnancy during and after the study. Some conditions like a history of severe allergies or certain infections mean you can't participate.
- Study Duration: Until the safety and effectiveness are thoroughly assessed.
- Visits: Regular visits are required for monitoring and treatment.
- Risks: Potential side effects from the combination treatments.
How understandable was the trial content above?
Hard to understand
Easy to understand